Select a medication above to begin.
Tecartus
brexucabtagene autoleucel
Black Box Warnings .
Cytokine Release Syndrome
including life-threatening reaction, has occurred; do not administer if active infection or inflammatory disorders; confirm minimum 2 doses tocilizumab available prior to infusion; treat severe or life-threatening CRS with tocilizumab /- corticosteroids; monitor patients daily for at least 7 days post-infusion, then monitor signs/symptoms x2wk after tx within proximity of healthcare facility; counsel patients on signs/symptoms and to seek immediate medical attention if they occur at any time
Neurological Toxicities
including life-threatening reaction, have occurred, including concurrently with CRS or after CRS resolution; provide supportive care and/or corticosteroids as needed; monitor patients daily for at least 7 days post-infusion, then monitor signs/symptoms x2wk after tx within proximity of healthcare facility
Secondary Hematological Malignancies
including T-cell malignancies, have occurred; monitor life-long; contact Kite at 1-844-454-5483 to report malignancy occurrence and obtain instructions on patient sample collection
Adult Dosing .
Dosage forms: INJ
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, prophylactic antimicrobials, and dosing
mantle cell lymphoma, relapsed or refractory
- [2 x10^6 chimeric antigen receptor (CAR)-positive viable T-cells/kg/dose IV x1]
- Start: 2 days after completing lymphodepleting combo chemo regimen cyclophosphamide + fludarabine; Max: 2 x10^8 CAR-positive viable T-cells/total dose
B-cell precursor ALL, relapsed or refractory
- [1 x10^6 chimeric antigen receptor (CAR)-positive viable T-cells/kg/dose IV x1]
- Start: 1 day after completing lymphodepleting combo chemo regimen cyclophosphamide + fludarabine; Max: 1 x10^8 CAR-positive viable T-cells/total dose
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.